1. A pharmaceutical composition comprising alovudine and zidovudine in a molar ratio in the range 1:100 to 1:350 and wherein the alovudine is present in the range 2-4 mg and the zidovudine is present in the range 300-900 mg.
2. A pharmaceutical composition according to claim 1 wherein the ratio is in the range 1:150 to 1:250.
3. A pharmaceutical composition according to claim 1, further comprising one or two additional pharmaceutical agents.
4. A pharmaceutical composition according to claim 3, wherein the additional pharmaceutical agent is the HIV antiviral MIV-170; or the additional pharmaceutical agent is the HIV antiviral MIV-160, alone or with a booster dose of ritonavir.
5. A pharmaceutical composition according to claim 1, presented in a QD unit dosage form.
6. A pharmaceutical composition according to claim 1 comprising 600 mg zidovudine.
7. A pharmaceutical composition according to any of claims 1 to 5, wherein the alovudine is administered as the alovudine monophosphate prodrug fosalvudine tidoxil.
8. A method for the treatment or prophylaxis of HIV comprising the simultaneous or sequential administration of alovudine and zidovudine in a ratio in the range 1:100 to 1:350.
9. A method according to claim 8, wherein the ratio is in the range 1:150 to 1:250.
10. A method according to claim 8, further comprising the simultaneous or sequential administration of one or two additional pharmaceutical agents.
11. A method according to claim 10, wherein the additional pharmaceutical agents comprise the HIV antiviral(s) MIV 170; or MIV-160 alone or with a booster dose of ritonavir.
12. A method according to claim 8, wherein the alovudine and zidovudine are presented in a QD unit dosage form.
13. A method according to claim 8, wherein the unit dosage form comprises 2-4 mg alovudine and 300-900 mg zidovudine.
14. A method according to claim 13, wherein the unit dosage form comprises 600 mg zidovudine.
15. A method according to claim 8 wherein the dose of alovudine is 2-4 mg QD and zidovudine 300 mg BID.
16. A method according to any of claims 8 to 15 wherein the alovudine is administered as the alovudine monophosphate prodrug, fosivudine tidoxil.
17. A kit of parts comprising:
(i) a pharmaceutical composition comprising alovudine; and
(ii) a pharmaceutical composition comprising zidovudine;
characterized in that that the alovudine and zidovudine are present in the kit at a molar ratio in the range 1:100 to 1:350.
18. The method according to claim 2, wherein the ratio is in the range of 1:150 to 1:200.
19. The method according to claim 9, wherein the ratio is in the range of 1:150 to 1:200.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. An IV catheter introducer comprising a tubular housing; a needle holder assembly having a tubular body slidably engaged inside the housing; a retraction mechanism seated in an annular space between the housing and the needle holder assembly; a plunger assembly having a plunger tube releasably engaged with the tubular body inside the housing; and a catheter attached by frictional engagement to the tubular housing; wherein
the needle holder assembly comprises a flash chamber with an interior space that is viewable through no more than two layers of clear plastic.